Immutep Ltd (IMMP) is a biotechnology company headquartered in Sydney, Australia, renowned for its clinical and preclinical product portfolio developments. The company is a global leader when it comes to developing innovative immunotherapeutic products for cancer and autoimmune diseases with strong potential for market growth.
Founded in 1987, the company was originally known as Prima BioMed Ltd., but it rebranded as imMuteP in 2017 to reflect its focus on immune-oncology. It engages in manufacturing cutting-edge therapeutics used in the treatment of serious diseases that affect the human immune system, utilizing its expertise in LAG-3, a vital immune checkpoint that plays a critical role in the body's immune response.
Immutep’s proprietary product portfolio is built around a set of technologies that leverage Lymphocyte Activation Gene-3 (LAG-3) or CD223 which is a critical immune checkpoint for cancer immunity. These LAG-3 products include lead product candidate, eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein that modulates the immune system to amplify anti-cancer immune responses.
The company’s key product candidates besides eftilagimod alpha include IMP761, an antibody product that suppresses the immune system and is being developed for the treatment of autoimmune diseases, and several partnered LAG-3 product candidates in development with big pharmaceutical companies like GlaxoSmithKline and Novartis Oncology.
Immutep has always taken a unique approach towards transforming the treatment of serious diseases, thereby arranging strategic partnerships and collaborations with other leading biotechnology and pharmaceutical companies around the world. Strong R&D investment with dedicated commitment towards innovation stands as a testimony to Immutep’s rise in the biopharmaceutical realm.
At the financial front, Immutep Ltd (IMMP) is listed on the NASDAQ and is also included in the Australian Securities Exchange. Creating shareholder value while focusing on the needs of the patients, this publicly traded company ensures broad access to its novel treatments.
From its inception until the present, Immutep has made significant contributions to medical research and the development of next-generation immunotherapy products. Its dedication to innovation and medical advancements has positioned it as a leader in the global biopharmaceutical industry, promising a healthier future for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Immutep (IMMP) has announced a 1-for-20 reverse ADS split to meet Nasdaq's minimum bid-price requirement, effective September 28, 2026. This move comes as the company's ADS price lingered below $1 for an extended period, despite its Price-to-Sales ratio suggesting investor optimism for future growth. Immutep, a clinical-stage biotechnology firm, has a weak GF Score™ of 27/100, reflecting poor profitability and momentum but moderate financial strength.
Immutep Ltd (AU:IMM) reported a significant increase in revenue for the year ending June 30, 2026, primarily due to a $14.6 million licensing deal with Dr Reddy's. However, the biotechnology company's after-tax loss widened to $79.3 million, driven by a substantial rise in research and development costs, an impairment on efti-related intangibles, and other financial pressures. The company's net tangible asset backing per share decreased, and it continues to operate without paying dividends as it focuses on clinical development.
Immutep Limited (ASX:IMM) reported a net loss of $79.3 million for the fiscal year ending June 30, 2026, a 29.1% increase from the previous year, primarily due to higher research and development expenses. The company's revenue was largely driven by licensing and collaboration with Dr Reddy's, but net tangible assets per security declined. Additionally, Immutep discontinued its TACTI-004 Phase III trial for non-small cell lung cancer based on an Independent Data Monitoring Committee recommendation.
Immutep Limited has released its August 2026 corporate presentation, detailing a cash balance of A$68.87 million as of June 30, 2026, which provides a financial runway into the first half of 2028. The company announced the discontinuation of its Phase III TACTI-004 trial, the termination of a licensing agreement with Novartis, and a new licensing deal with Dr. Reddy's for efti, alongside ongoing cost-reduction efforts. Immutep's pipeline includes four clinical-stage assets for cancer and autoimmune diseases, supported by a strong intellectual property portfolio.
Short interest in Prima BioMed Ltd (NASDAQ:IMMP) significantly dropped by 44.4% in July, totaling 1,195,547 shares as of July 31st. This represents 0.8% of outstanding shares and a 5.4-day-to-cover ratio. While institutional ownership remains low at 2.32%, analyst sentiment is mixed, with a consensus "Hold" rating and a $5.50 target price, despite the stock trading near its 52-week low.